EUROBIO SCIENTIFIC acquired by NEXTSTAGE & IK PARTNERS
Context
EB Development (Consortium: NextStage AM & IK Partners) has successfully concluded its takeover bid for Eurobio Scientific, following the results of a reopened offer period. The consortium now holds 88.92% of the share capital and voting rights (including treasury shares). The offer was initiated to take the company private and provide the management team, led by Denis Fortier, with the flexibility to pursue an aggressive external growth strategy. While the bid secured a significant majority, the final participation fell just short of the 90% threshold required for a mandatory squeeze-out (retrait obligatoire). Consequently, the conditional additional price of €1.25 per share (linked to reaching the 90% mark) will not be paid to tendering shareholders. Despite remaining listed for the time being, the transaction effectively shifts Eurobio into a "private-equity-backed" development phase, allowing for deeper consolidation of the European in vitro diagnostics market.
EUROBIO SCIENTIFIC, which reported an EBITDA margin of in 2024, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.5x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Eurobio Scientific is a leading French player in the field of in vitro diagnostics (IVD) and "intelligent health." The company’s business model is vertically integrated, encompassing the design, development, and commercialization of specialty diagnostic kits alongside the distribution of high-end reagents and equipment for clinical laboratories and research centers. A key pillar of its value proposition is its focus on high-added-value proprietary products, reinforced by strategic acquisitions such as the 2022 purchase of GenDx, a global leader in HLA typing for transplant compatibility. Eurobio Scientific played a critical role in the post-Covid diagnostic landscape by shifting its focus toward proprietary innovation and international expansion. Operating as an "ETI" (Intermediate-Sized Enterprise), the company leverages its deep technical expertise to serve the transplantation, infectious diseases, and oncology markets, aiming to become a pan-European leader in specialized diagnostics.
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (EUR)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 01/2025 | Animalcare Group | Randlab | AUSTRALIA | Animal Health |
| 01/2025 | QUADRIVIO GROUP | MIR - MEDICAL INTERNATIONAL RESEARCH | ITALY | Diagnostic Equipment |
| 12/2024 | GOLDMAN SACHS | Synthon International | NETHERLANDS | Generics / Labs |
| 12/2024 | UI INVESTISSEMENT | DIDACTIC | FRANCE | Medical Consumables |
| 11/2024 | NAXICAP PARTNERS | GLOBAL D | FRANCE | Implants & Prosthetics |
| 10/2024 | KKR / KREFELD | ANJAC BEAUTY & HEALTH | FRANCE | CDMO |
| 10/2024 | CLAYTON, DUBILIER & RICE (CD&R) | OPELLA | FRANCE | Generics / Labs |
| 10/2024 | BANSK GROUP | PETIQ | UNITED STATES | Animal Health |
| 09/2024 | AGILENT TECHNOLOGIES | BIOVECTRA | CANADA | CDMO |
| 08/2024 | NORDSON CORPORATION | ATRION CORPORATION | UNITED STATES | Diagnostic Equipment |
REFERENCES
Valuation range: EV 100M - 350M EUR
Revenue range: 100M - 200M EUR
EBITDA range: 5M - 25M EUR
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of EUROBIO SCIENTIFIC by NEXTSTAGE / IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: nextstage / ik partners